Notably, MET exon 14 alterations, which resulted in increased MET protein levels due to disrupted ubiquitin mediated degradation and considered as a viable therapeutic target in NSCLC [20, 21], was not detected in those sensitive HCC cell lines. This evidence concerns the gene MET and non-small cell lung carcinoma.